Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects with Type 2 Diabetes Mellitus Protocol # WEL-A-U307

263239
Pediatrics, Diabetes
Holley Allen, MD, MSPH
Baystate Children's Specialty Center
50 Wason Ave
Springfield, MA

The purpose of this study is to evaluate the safety and tolerability of Welchol® (colesevelam HCl) as a treatment for children/adolescents with Type 2 Diabetes.

  • Type 2 Diabetes
  • Ages 10-17
  • A1C 7.0-10.0%
  • No insulin therapy (ever or within > 14 days of study screening)
Rebecca Feinberg
413-794-7318